

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. AU 2014340006 B2

(54) Title
Chitosan stenting paste

(51) International Patent Classification(s)
A61L 26/00 (2006.01) **A61L 24/08** (2006.01)
A61L 24/00 (2006.01) **A61L 27/20** (2006.01)

(21) Application No: **2014340006** **(22) Date of Filing:** **2014.10.23**

(87) WIPO No: **WO15/061606**

(30) Priority Data

(31) Number	(32) Date	(33) Country
14/319,901	2014.06.30	US
14/061,993	2013.10.24	US

(43) Publication Date: **2015.04.30**
(44) Accepted Journal Date: **2018.06.28**

(71) Applicant(s)
Medtronic Xomed, Inc.

(72) Inventor(s)
Medina, Jennifer Gates;Sherman, Ethan Glenn

(74) Agent / Attorney
FB Rice Pty Ltd, L 23 44 Market St, Sydney, NSW, 2000, AU

(56) Related Art
WO 2002/040072 A2
WO 2011/060545 A1
US 2003/0143274 A1
WO 1999/007416 A1
WO 1996/013284 A1
WO 2010/033943 A1
CHELLADURAI S et al., 'Design and Evaluation of Bioadhesive in-Situ Nasal Gel of Ketorolac Tromethamine', Chemical & Pharmaceutical Bulletin. 2008, vol. 56, no. 11, pages 1596-1599

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau



(10) International Publication Number

WO 2015/061606 A1

(43) International Publication Date

30 April 2015 (30.04.2015)

WIPO | PCT

(51) International Patent Classification:

A61L 26/00 (2006.01) *A61L 27/20* (2006.01)
A61L 24/00 (2006.01) *A61L 24/08* (2006.01)

(74) Agent: CLEVELAND, David, R.; Iplm Group, P.A., Post Office Box 18455, Minneapolis, MN 55418 (US).

(21) International Application Number:

PCT/US2014/062029

(22) International Filing Date:

23 October 2014 (23.10.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

14/061,993 24 October 2013 (24.10.2013) US
14/319,901 30 June 2014 (30.06.2014) US

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(71) Applicant: MEDTRONIC XOMED, INC. [US/US];
6743 Southpoint Drive North, Jacksonville, FL 32216-0980 (US).

(72) Inventors: MEDINA, Jennifer, Gates; 6743 Southpoint Drive North, Jacksonville, FL 32216-0980 (US). SHERMAN, Ethan, Glenn; 6743 Southpoint Drive North, Jacksonville, FL 32216-0980 (US).

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: CHITOSAN STENTING PASTE



(57) Abstract: Nasal or sinus sites are treated with a ready-to-use paste having a high concentration of a water-soluble chitosan and an osmolality reducing agent dissolved in a phosphate- containing solution. The ingredients provide a paste at room temperature and have a pH of at least 4. The osmolality reducing agent does not crosslink with the water-soluble chitosan. The paste provides stenting, adheres to the nasal or sinus site and has a residence time of at least 1 day.

Fig. 1



Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*

CHITOSAN STENTING PASTE

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority from U.S. Patent Application Serial No. 14/061,993, filed October 24, 2013 and entitled CHITOSAN STENTING PASTE and U.S. Patent Application Serial No. 14/319,901, filed June 30, 2014 and entitled CHITOSAN PASTE WOUND DRESSING, and is related to International Application No. (Attorney Docket No. C04881WO02), filed even date herewith and entitled CHITOSAN PASTE WOUND DRESSING, the disclosures of each of which are incorporated herein by reference.

FIELD OF THE INVENTION

[0002] This invention relates to biomaterials for use in or on tissue and structures in the throat, nasal passages and elsewhere in or near the respiratory tract.

BACKGROUND

[0003] Sinusitis is an inflammation of the mucosal tissue lining of the sinus walls which may lead to nasal passageway blockage, mucous stagnation and bacterial or fungal sinus cavity infection. Typical treatments begin with antibiotics. However, when antibiotics cannot relieve sinusitis, sinus surgery (which involves opening the sinus cavities and removing mucosal tissue) may be an alternative. Post-operative care for such surgery requires temporary and uncomfortable sinus packing or gauze which supports the reopened sinus passage and absorbs excess fluid while the tissues heal. After several days or at the discretion of the physician, the gauze packing is removed. Doing so is painful.

[0003A] Any discussion of documents, acts, materials, devices, articles or the like which has been included in the present specification is not to be taken as an admission that any or all of these matters form part of the prior art base or were common general knowledge in the field relevant to the present disclosure as it existed before the priority date of each of the appended claims.

SUMMARY OF THE INVENTION

[0004] Sinus sealants and other biological materials have emerged as a promising

technique to temporarily seal, stent or otherwise protect post-operative sinus passageways with less intrusion and pain than traditional packing techniques.

[0005] Packing or biomaterial stents that dissolve or otherwise degrade over a certain period are desirable. The packing or stents desirably should be able to be dispensed through a suitable dispensing device (for example, a syringe) using a single, gloved hand. Packing or stents should also desirably be provided as ready-to-use injectable or extrudable compositions.

[0006] The invention provides, in one aspect, a sinus stent paste comprising a water-soluble chitosan or derivative thereof and an osmolality reducing agent dissolved in a phosphate-containing solution to provide an opaque paste at room temperature containing at least 5 wt. % of the water-soluble chitosan or derivative thereof based on the total paste weight and having a pH of at least 4, a viscosity of about 1 to about 15 Pa.s., an osmolality of about 270 to about 2000 mOsm/kg, and a residence time of at least 1 day, wherein the osmolality reducing agent does not crosslink with the water-soluble chitosan.

[0007] The invention provides, in another aspect, a method for preparing a chitosan stenting paste comprising the step of:

mixing and dissolving a water-soluble chitosan or derivative thereof and an osmolality reducing agent in a phosphate-containing solution to provide an opaque paste at room temperature containing at least 5 wt. % of the water-soluble chitosan or derivative thereof based on the total paste weight and having a pH of at least 4, a viscosity of about 1 to about 15 Pa.s., an osmolality of about 270 to about 2000 mOsm/kg, and a residence time of at least 1 day, wherein the osmolality reducing agent does not crosslink with the water-soluble chitosan.

[0008] The invention provides in yet another aspect, a method for stenting comprising:

- a) providing a composition comprising a water-soluble chitosan or derivative thereof and an osmolality reducing agent dissolved in a phosphate-containing solution to provide an opaque paste at room temperature containing at least 5 wt. % of the water-soluble chitosan or derivative thereof based on the total paste weight and having a pH of at least 4, a viscosity of about 1 to about 15 Pa.s., and an osmolality of about 270 to about 2000 mOsm/kg, wherein the osmolality reducing agent does not crosslink with the water-soluble chitosan; and

b) applying the paste onto a nasal or sinus site to form a protective packing, layer or stent wherein the paste adheres to the nasal or sinus site and has a residence time of at least 1 day.

[0009] The invention provides, in an additional aspect, use of a paste composition for stenting internal tissue or an internal surgical site, the composition comprising a water-soluble chitosan or derivative thereof and an osmolality reducing agent dissolved in a phosphate-containing solution to provide a paste at room temperature having a pH of at least 4, a viscosity of about 1 to about 15 Pa.s., an osmolality of about 270 to about 2000 mOsm/kg, and a residence time of at least 1 day, wherein the osmolality reducing agent does not crosslink with the water-soluble chitosan.

[0010] The disclosed paste, stent, method and use are especially useful for nasal and sinus surgery.

[0010A] Throughout this specification the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element, integer or step, or group of elements, integers or steps, but not the exclusion of any other element, integer or step, or group of elements, integers or steps.

BRIEF DESCRIPTION OF THE DRAWING

[0011] **Fig. 1** is a schematic view showing application of the disclosed paste to stent the middle turbinate.

[0012] **Fig. 2** and **Fig. 3** are perspective views respectively showing a syringe and bendable tip for use in dispensing the disclosed paste.

[0013] Like reference symbols in the various figures of the drawing indicate like elements. The elements in the drawing are not to scale.

DETAILED DESCRIPTION

[0014] The following detailed description describes certain embodiments and is not to be taken in a limiting sense. All weights, amounts and ratios herein are by weight, unless otherwise specifically noted. The terms shown below have the following meanings:

[0015] The term "adhesion" refers to the sticking together of a body structure or prosthetic material to tissue, to the sticking together of tissue to tissue with which it is in intimate contact for an extended period, or to the formation of tissue that connects body

structures, prosthetic materials or tissues to one another across a normally open space.

[0016] The term “antimicrobial” when used in reference to a substance means that the substance can kill, significantly inhibit or control the growth of microbes, for example bacteria such as *Staphylococcus aureus*, *Streptococcus epidermidis*, *Pseudomonas aeruginosa* or *Escherichia coli*.

[0017] The term “biocompatible” when used in reference to a substance means that the substance presents no significant deleterious or untoward effects upon the body.

[0018] The term “biodegradable” when used in reference to a substance means that the substance will degrade or erode in vivo to form smaller chemical or physical species. Such degradation process may be enzymatic, chemical or physical.

[0019] The term “chitosan” refers to a polysaccharide polymer containing randomly distributed β -(1-4)-linked D-glucosamine (deacetylated) and optional N-acetyl-D-glucosamine (acetylated) monomer units, and includes chitosan derivatives in which one or more hydroxyl or amine groups of the polymer have been modified to alter the solubility or mucoadhesion characteristics of the derivative.

[0020] The term “conformal” when used in reference to a paste applied to tissue or other body structure means that the paste can form a substantially continuous layer over an area to which the paste has been applied.

[0021] The term “hemostat” means a device or material which stops blood flow.

[0022] The term “mucoadhesive” when used in reference to a substance means that the substance will adhere to the mucus covering epithelia.

[0023] The term “nasal or sinus” refers to the various tissues defining the normally air-filled passages and chambers within the nose and sinus cavities including but not limited to the nostrils or nares, the nasal concha or turbinates, the frontal, ethmoid, sphenoid and maxillary sinuses, the sinus ostia and the nasopharynx.

[0024] The term “opaque” when used in reference to a material means that ordinary overhead illumination is not transmitted through about a 4 mm thick layer of the material.

[0025] The term “osmolality” means the number of osmoles of solute per kilogram of solvent, as measured using a freezing point depression osmometer.

[0026] The term “paste” when used in reference to a substance means the substance is a visibly homogenous, nonporous, opaque material having a soft, malleable, spreadable consistency, for example similar to toothpaste, and a viscosity such that the material is suitable for use in stenting (*e.g.*, holding apart) nasal or sinus tissue. An opaque gel may be a paste. A collection of free flowing dry solid particles, a non-malleable solid, a porous sponge, a translucent gel, a liquid or a sprayable composition would not be a paste.

[0027] The term “protective” when used in reference to a paste applied to tissue or other body structure means that the paste may assist in returning an injured, inflamed or surgically repaired tissue surface to a normal state, *e.g.*, through one or more healing mechanisms such as modulation of an inflammatory response, phagocytosis, mucosal remodeling, reciliation or other full or partial restoration of normal function.

[0028] The term “residence time” when used in reference to a paste applied to tissue or other body structure means the time period during which the paste or portion thereof remains in place *in vivo* under gross observation.

[0029] The term “room temperature” means a temperature of 20-25° C.

[0030] The term “thin” when used in reference to a protective layer atop tissue or other body structure means having an average thickness less than about five millimeters.

[0031] The term “tonicity” when used in reference to a cell’s response (*e.g.*, ciliated tissue such as found in the ear, nose and throat) to an external substance refers to the sum of the concentration of solutes having the capacity to exert an osmotic force across a given membrane. Solutes that cannot cross the cell membrane exert an osmotic force.

Depending on the solute concentration of the substance in reference to the cell membrane, tonicity may be referred to as “hypertonic”, “hypotonic” or “isotonic”. “Hypertonic” refers to a substance with a higher solute concentration outside a cell membrane. As such, when the substance contacts the cell membrane, water in the cell will have a tendency to move out of the cell to balance the solute concentration outside the cell membrane.

“Hypotonic” refers to substance with a lower solute concentration outside the cell membrane. As such, water from outside the cell will enter into the cell, causing swelling in an attempt to balance the solute concentration inside the cell. “Isotonic” refers to a substance’s solute concentration that is the same as the cell to which it comes in contact. As such, it is considered physiological with the cell and hence there is no net flow of water.

[0032] The term “viscosity” when used in reference to a substance is the extent to which the substance resists a tendency to flow when subjected to stress. Viscosity may be measured with a cone and plate viscometer that imposes a specific stress on the substance and the resultant stress deformation or resistance is measured according to ASTM F2103-11 (Part 5). The units of viscosity are reported as Pascal-seconds (Pa.s.). For the disclosed pastes, viscosity values are determined and reported after the paste has been sterilized.

[0033] The disclosed paste or method includes a high concentration of a water-soluble chitosan (*e.g.*, chitosan salt) and an osmolality reducing agent dissolved in a phosphate-containing solution, the paste having a pH of at least 4. The disclosed paste desirably has

an off white to yellowish coloration, which makes it easy to visualize when applied. The disclosed paste may desirably be opaque. The disclosed paste is also desirably provided in a ready-to-use, storage-stable, injectable or extrudable form, requiring no or minimal preparation. The osmolality reducing agent is desirably not a chitosan nor is the osmolality reducing agent crosslinkable with the chitosan. Because the paste desirably does not include crosslinkers, it can be stored for extended time periods and desirably does not require further hydration, mixing or other similar preparation steps before application.

[0034] The disclosed paste may be prepared by mixing or dissolving the initially solid ingredients (*e.g.*, water-soluble chitosan and an osmolality reducing agent) in a phosphate-containing solution (*e.g.*, phosphate-buffered saline (PBS)). A paste is formed at room temperature (*e.g.*, about 20° C to about 25° C) when the ingredients become solubilized and remains a paste at room temperature.

[0035] Referring to **Fig. 1**, the disclosed paste or method may be used or performed for example in the nasal or sinus cavities **100** of a patient, including the maxillary sinuses **110a**, **110b**, frontal sinuses **112a**, **112b**, which may be accessed through nares **114a**, **114b** and turbinates **116a**, **116b**. It should be noted that external features of the patient, including nares **114a**, **114b**, are shown in dashed lines. When the patient suffers for example from chronic rhinosinusitis, one or more treatment sites such as treatment site **118** associated with the middle turbinate **116a** may be medically or if need be surgically addressed. A layer **120** of the disclosed paste may be applied to site **118** and allowed to remain in place while healing takes place.

[0036] **Fig. 2** shows a dispensing syringe **200** for the disclosed paste held in the right hand **202** of a surgeon. When plunger **204** is depressed into syringe barrel **206**, the disclosed paste is dispensed through straight tip **208** and bendable tip **210**, whereupon it exits tip **210** as an opaque mass **220**. **Fig. 3** shows various bent positions (in phantom) that may be formed in bendable tip **210** to facilitate access to difficult to reach portions of a patient's anatomy.

[0037] Those skilled in the art will appreciate that the disclosed paste may be applied in or to other body parts. The disclosed paste may for example have utility in vascular or non-vascular applications, including treatment of tissues (*e.g.*, mucosal tissues) or other internal tissues or structures in or near the ears, throat, limbs or spinal column.

[0038] The applied paste may fill the treatment site (*e.g.*, a nasal or sinus cavity, or an opening, recess, passageway or joint in a portion of the limbs or spinal column), in which case the disclosed paste may be very thick and not exposed to air or other nearby gases, and with differing thicknesses throughout. The disclosed paste may also be applied as a thin film or other conformal coating in which case the layer may be relatively thin and exposed to air or other nearby gases, and with a substantially uniform thickness throughout the layer. The protective paste desirably adheres to mucosal or other natural tissues (*e.g.*, cartilage or bone) at the treatment site and resists detachment or other disruption until natural degradation or degradation initiated by irrigation or hydrolysis takes place, *e.g.*, after a residence time *in vivo* from at least 1 day, at least 3 days, at least 5 days, at least 7 days, at least 15 days, up to about 3 weeks, up to about 4 weeks, up to about 45 days or up to about 60 days. Meanwhile bacterial recolonization or reinfection may be significantly reduced or prevented, and improved healing (*e.g.*, reciliation) may take place. The protective paste may provide various therapeutic advantages including but not limited to bacterial adhesion inhibition, anti-infective properties, local immune modulation, tissue protection, reduction or elimination of pain or bleeding, reduction in inflammation, optimization of environment for ciliary regrowth, reduction in adhesions to critical anatomy, and the like. These advantages may arise due to a variety of mechanisms including a) killing bacteria, b) inhibiting bacterial colonization, c) inhibiting the adherence of bacteria to tissue, d) reducing tissue morbidity or abscess formation, e) reducing or preventing disease recurrence (for example, specifically reducing the chronic inflammation related to bacterial toxin and extracellular polysaccharide matrix (*viz.*, biofilm) toxin), f) coating and protecting tissue during healing, such as by maintenance of a moist wound which promotes platelet aggregation, or by closure of a dry wound without excessive scabrous formation, g) hemostasis, h) optimizing the environment for reciliation of the mucosa, i) speeding the growth or regrowth of cilia and j) delivering therapeutic agent(s) to the treatment site.

[0039] Desirably the protective paste will adhere to a portion of the mucosa while leaving the cilia in unadhered portions free to undergo natural rhythmic cilia motion (*viz.*, cilia beating), if desired also will deliver antimicrobial agents or additional therapeutic

agents, and desirably will discourage or prevent bacteria from colonizing on the treatment site.

[0040] Water-soluble chitosans, preferably chitosan salts may be used to form the paste. For example, high concentrations of a chitosan salt may be mixed in a phosphate-containing solution (*e.g.*, PBS, glycerol phosphate disodium salt hydrate or any combination thereof) to provide a ready-to use paste. The high chitosan salt concentration contributes both to the osmolality and opacity of the resulting paste. Without intending to be bound by theory, the phosphate and chitosan may react via an ionic reaction to help form the paste. The chitosan desirably is sufficiently water-soluble so that all of the desired chitosan amount can be dissolved in the disclosed paste. A portion of the chitosan may however be dispersed in the disclosed paste. The chosen chitosan preferably has a water solubility of at least about 3 wt. %, at least about 5 wt. %, at least about 8 wt. %, at least about 10 wt. %, at least about 15%, at least about 18% or at least about 20 wt. %. Exemplary chitosan concentrations may be from about 3 to about 20 wt. %, about 5 to about 8 wt. %, about 8 wt. % to about 12 wt. %, about 12 wt. % to about 18 wt. %, about 16 wt. % to about 18 wt. % or about 18 wt. % to about 20 wt. % of the total paste weight. The high chitosan concentrations used in the paste result in viscosities desirable for good stenting and acceptable syringe delivery force. Desired viscosities range from about 1 to about 15 Pa.s. when tested at 25° C and a shear rate of 221s⁻¹. This shear rate correlates to the approximate average shear rate the substance may experience as it is dispensed through a standard 30 ml BD™ syringe with a LUER LOCK™ connector at a rate of 1 ml/s.

[0041] Exemplary unmodified, water-soluble chitosans and their salts (including chloride, citrate, nitrate, lactate, phosphate, and glutamate salts) may be obtained from a variety of commercial sources including sources described in U.S. Patent Application Publication No. US 2009/0291911 A1.

[0042] Chitosan may also be synthesized by deacetylation of chitin (poly-N-acetyl-D-glucosamine) to eliminate acetyl groups on the nitrogen atom by hydrolysis. The resulting polymer has a plurality of repeating units (*e.g.*, about 30 to about 3000 repeating units, about 60 to about 600 repeating units, or such other amount as may be desired for the chosen end use) some or all of which contain deacetylated amino groups (*e.g.*, about 30 to

about 100% or about 60 to about 95% of the total repeating units), with the remaining repeating units (if any) containing acetylated amino groups. The polymer is cationic and may be regarded as being composed from glucosamine monomers.

[0043] The chitosan may have a variety of number average molecular weights, *e.g.*, about 5 to about 2000 kDa, about 10 to about 500 kDa, or about 10 to about 100 kDa. The chitosan may for example be an ultralow molecular weight material having a number average molecular weight less than or about 30 kDa, a low molecular weight material having a number average molecular weight of about 30 to about 400 kDa, a medium molecular weight material having a number average molecular weight of about 200 to about 500 kDa or a high molecular weight material having a number average molecular weight greater than about 500 kDa. A low molecular weight chitosan is preferred. The disclosed molecular weights are weights before sterilization of the paste. The chitosan desirably is in dry particulate form prior to mixing with the phosphate solution, for example, as free-flowing granules whose average particle diameter is less than about 1 mm, less than about 100 μ m, about 1 to about 80 μ m, or less than 1 μ m.

[0044] Chitosan derivatives may also be employed, for example derivatives in which one or more hydroxyl or amino groups have been modified for the purpose of altering the solubility or mucoadhesion characteristics of the derivative. Exemplary derivatives include thiolated chitosans, and non-thiolated chitosan derivatives such as acetylated, alkylated or sulfonated chitosans (for example O-alkyl ethers, O-acyl esters, cationized trimethyl chitosans and chitosans modified with polyethylene glycol). Chitosan derivatives may be obtained from a variety of sources. For example, thiolated chitosans may be obtained from ThioMatrix Forschungs Beratungs GmbH and Mucobiomer Biotechnologische Forschungs-und Entwicklungs GmbH or prepared by reaction of chitosan with a suitable thiolated reactant, *e.g.*, as described in Published PCT Application No. WO 03/020771 A1 or in Roldo et al., *Mucoadhesive thiolated chitosans as platforms for oral controlled drug delivery: synthesis and in vitro evaluation*, European Journal of Pharmaceutics and Biopharmaceutics, 57, 115–121 (2004); Krauland et al., *Viscoelastic Properties of a New in situ Gelling Thiolated Chitosan Conjugate*, Drug Development And Industrial Pharmacy, 31, 885-893 (2005); Bernkop-Schnürch, *Thiomers: A new generation of mucoadhesive polymers*, Advanced Drug Delivery Reviews, 57, 1569-1582

(2005); and Bernkop-Schnürch et al., *Thiomers: Preparation and in vitro evaluation of a mucoadhesive nanoparticulate drug delivery system*, International journal of Pharmaceutics, 317, 76-81 (2006).

[0045] While a high chitosan concentration has a desired viscosity for stenting, it also results in high osmolality (e.g., a paste made from about 18 wt. % chitosan HCl and having a molecular weight in the range of about 30 to about 400 kDa results in an osmolality of about 2800 mOsm/kg). A high osmolality paste may not be physiologically compatible with the cells or tissues to which the paste may be applied. The desired osmolality is such that the paste is considered isotonic or hypertonic to the cells or tissues (e.g., ciliated tissue) to which the paste is applied. It is preferable that the paste have an osmolality of less than about 2000 mOsm/kg, for example from about 270 to about 2000 mOsm/kg or about 270 to about 1500 mOsm/kg, yet has a desirable viscosity.

[0046] To maintain or lower the osmolality without significantly altering or reducing the desired viscosity or the paste-like consistency, it was found that one or more osmolality reducing agents may be used. The osmolality reducing agent desirably is sufficiently water-soluble so that all of the desired amount of the osmolality reducing agent can be dissolved in the disclosed paste. A portion of the osmolality reducing agent may however be dispersed in the disclosed paste. The chosen osmolality reducing agent preferably has a water solubility of at least about 1 wt. %, at least about 2 wt. %, at least about 8 wt. %, at least about 10 wt. %, or at least about 20 wt. %. The osmolality reducing agent desirably contains few or no salt groups as such groups may increase rather than decrease the osmolality of the disclosed paste. Recommended amounts of the osmolality reducing agent may for example be about 1 to about 20 wt. %, about 1 to about 10 wt. % or about 2 to about 8% wt. of the total paste weight. Examples of suitable osmolality reducing agents include polysaccharides other than chitosans that are biocompatible and which reduce osmolality in the disclosed paste but which do not crosslink the chitosan. Examples of such polysaccharides include agars, alginates, carrageenans, celluloses, dextrans, galactomannans, glycogens, hyaluronic acids, and starches, and especially those that are water-soluble to the desired extent without containing salt groups.

[0047] Preferred polysaccharides include hydroxyl-functional or alkyl-modified celluloses. Exemplary cellulose materials include methylcellulose, ethylcellulose,

hydroxybutyl methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropyl methylcellulose, carboxymethylcellulose, and mixtures thereof. Without intending to be bound by theory, it is believed that the osmolality reducing agent serves as a “salt scavenger” that may help reduce the paste’s osmolality and maintain the desired paste-like consistency.

[0048] The paste may for example contain chitosan and an osmolality reducing agent in a combined amount representing about 1 to about 20 wt. %, about 10 to about 20 wt. % or about 10 to about 15 wt. % of the total paste composition. The chitosan and osmolality reducing agent may for example be combined in a ratio of about 10:1 to about 1:20, about 5:1 to about 1:10, or about 3:1 to about 1:5.

[0049] The paste desirably has a pH appropriate for contacting human tissue, *e.g.*, a pH of at least 4, a near-neutral pH, or a pH less than 10. An acid, base or buffering agent may for example be included to help maintain an appropriate pH. Buffering agents are preferred and phosphate-containing buffers are most preferred. Exemplary buffering agents include mixtures of barbitone sodium, glycinamide, glycine, potassium chloride, potassium phosphate, potassium hydrogen phthalate, sodium acetate, sodium citrate or sodium phosphate with their conjugate acids (for example a mixture of sodium citrate and citric acid).

[0050] Exemplary phosphate-containing buffers are derived from phosphoric acid and a base selected from potassium hydroxide, sodium hydroxide, the potassium or sodium salts of phosphoric acid, mixtures thereof and the like. Exemplary phosphate salts include sodium phosphate dibasic and monobasic, potassium phosphate dibasic and monobasic and mixtures thereof. The concentration of phosphoric acid and base or salt in the disclosed buffering agent may be varied to achieve the desired pH.

[0051] As discussed above, the chitosan and the osmolality reducing agent are desirably dissolved in the phosphate-containing solution. Exemplary phosphate-containing solutions include phosphate-containing buffers such as PBS. PBS solutions typically include a combination of one or more phosphate salts and one or more chloride salts. Exemplary phosphate salts include disodium phosphate, potassium dihydrogen phosphate or a combination thereof. Exemplary chloride salts include sodium chloride, potassium chloride or a combination thereof. The salts used to prepare the PBS solution

are optionally hydrates. An exemplary combination of salts employs disodium phosphate heptahydrate ($\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$) and potassium dihydrogen phosphate (KH_2PO_4), in a so-called 1X PBS solution with concentrations of about 0.01M phosphate, about 0.0027M KCl, about 0.137 M NaCl and a pH of 7.4 at 25° C. PBS buffer solutions may be prepared in other strengths such as 2X, 3X, 5X, 10X or any other suitable strength. For example, a 10X PBS buffer may be prepared by adding 10 times the ingredients described for a 1X PBS buffer to result in concentrations of about 0.1M phosphate, about 0.027M KCl, and about 1.37 M NaCl. Preferably, the phosphate-containing solution is a PBS solution and more preferably is greater than a 1X PBS solution. Preferably, the PBS solution has a pH between about 9 to about 12, and more preferably is a 3X solution having a pH of about 11.

[0052] Phosphates may also be provided as salts of glycerol-3-phosphate (GlyPhos) (e.g., as sodium, potassium, calcium or magnesium salts). Stereoisomeric forms of GlyPhos, preferably the racemic, meso, α and β blends or other forms or blends, may also be used. In some embodiments, the phosphate may be provided by a buffering agent (e.g., PBS), by a salt of GlyPhos or both.

[0053] The disclosed paste may consist of or consist essentially of the above-mentioned water-soluble chitosan or derivative, osmolality reducing agent and phosphate-containing solution, optionally together with any one or more of a variety of adjuvants. Exemplary adjuvants include lubricants, wetting agents, therapeutic agents, antimicrobial agents, dyes, pigments or other colorants, indicators, flavoring or sweetening agents, antioxidants, antifoam agents, thixotropes, release agent modifiers for sustained or delayed release of therapeutic agents, and other ingredients that will be known to persons having ordinary skill in the art.

[0054] Lubricants and wetting agents are especially desirable adjuvants that may help maintain paste consistency, and may aid in dispensing the paste into or onto a desired treatment site. Desirably, the paste should be able to be dispensed by an operator from a suitable delivery device (for example a syringe) using a single gloved hand. One preferred class of lubricants and wetting agents includes hydroxy compounds having two or more hydroxyl groups with the presence of 1,2-diol grouping being desirable. Hydroxy compounds having 2-4 carbon atoms have been found to be particularly useful lubricants.

Glycerol is especially preferred. Other compounds include ethane-1,2-diol; propane-1,2-diol; butane-1,3-diol and butane-1,4-diol. Mixtures of hydroxy compounds may be employed, especially mixtures of glycerol and one or more diols. Desired amounts of the lubricants and wetting agents may for example be about 1 to about 15 wt. % or about 2 to about 12 wt. % of the total paste weight.

[0055] Exemplary therapeutic agents include any material suitable for use at the intended treatment site including analgesics, anti-cholinergics, anti-fungal agents, antihistamines, steroidal or non-steroidal anti-inflammatory agents, anti-parasitic agents, antiviral agents, biostatic paste, chemotherapeutic agents, antineoplastic agents, cytokines, decongestants, hemostatic agents (*e.g.*, thrombin), immunosuppressors, mucolytics, nucleic acids, peptides, proteins, steroids, vasoconstrictors, vitamins, mixtures thereof, and other therapeutic materials that will be known to those skilled in the art. A useful list of such therapeutic agents may also be found, for example, in U.S. Patent No. 7,959,943 B2 (Hissong et al.).

[0056] The disclosed paste desirably is inherently antimicrobial without requiring addition of a separate antimicrobial agent. Antimicrobial activity may be influenced by the proportion of chitosan in the paste. A separate antimicrobial agent may be employed if desired. A useful list of such antimicrobial agents may be found, for example, in U.S. Patent No. 7,959,943 B2.

[0057] Exemplary dyes, pigments or other colorants include FD & C Red No. 3, FD & C Red No. 20, FD & C Yellow No. 6, FD & C Blue No. 2, D & C Green No. 5, D & C Orange No. 4, D & C Red No. 8, caramel, titanium dioxide, fruit or vegetable colorants such as beet powder or beta-carotene, turmeric, paprika and other materials that will be known to those skilled in the art). Exemplary indicators; flavoring or sweetening agents include anise oil, cherry, cinnamon oil, citrus oil (*e.g.*, lemon, lime or orange oil), cocoa, eucalyptus, herbal aromatics (*e.g.*, clove oil, sage oil or cassia oil), lactose, maltose, menthol, peppermint oil, saccharine, sodium cyclamate, spearmint oil, sorbitol, sucrose, vanillin, wintergreen oil, xylitol and mixtures thereof.

[0058] The disclosed paste typically will be placed in suitable sealed packaging (for example, a syringe, a vial, or pouch made of suitable materials, or a kit containing such packaging and optional printed instructions) and subjected to sterilization before being

further packaged if need be with printed instructions describing the proper use of the paste or kit in nasal or sinus surgery. Sterilization methods that do not unduly discolor (*e.g.*, brown), affect the adhesive strength or viscosity or otherwise unduly affect the paste's consistency are desirable. Suitable sterilization methods include steam or ionizing radiation (*e.g.*, gamma radiation and electron beam (E-Beam)). E-Beam sterilization appears to prevent or limit paste discoloration. E-beam sterilization may be performed at reduced temperatures as described in U.S. Patent No. 8,653,319 B2 (Amery et al). E-beam or gamma sterilization may for example be used at doses in the range of about 12 to about 40 kGy. In some embodiments the disclosed paste may be translucent before sterilization and opaque after sterilization.

[0059] The paste desirably is provided as a ready-to-use composition requiring little or no mixing, stirring, hydration or other preparation. The paste desirably is provided in a dispenser from which the paste may be injected or extruded, and may for example be packaged in unit doses of about 5 to about 100 g. The paste desirably has good shelf life as determined by adhesive strength, viscosity and pH, and preferably may be stored for more than 12 months. In some embodiments, the paste may be stored for more than 15 months, more than 18 months or up to 24 months while still maintaining a viscosity of about 1 to about 15 Pa.s. If the paste appears to have separated, re-mixing (*e.g.*, moving the composition back and forth between two syringes) typically will return the paste to a more homogenous consistency. However, the paste preferably does not separate during storage. The paste desirably is stable at temperatures ranging from about 2° C to about 60° C. In addition, the paste desirably remains a paste after exposure to extreme temperature ranges imposed during ISTA-2A testing (*e.g.*, about -29°C to about 60°C).

[0060] The disclosed paste also may have desirable mucoadhesion. In other words, the disclosed paste preferably will adhere or stick to the specific body tissue or passageway to which it is applied without having to fully pack the passageway to obtain adequate retention in the passageway. Desirably, the paste has an adhesive strength such that a separation force of about 5 grams to about 80 grams, about 20 to about 50 grams or about 15 to about 30 grams may be required. The separation force may be measured as the force required when using a tensile testing machine (*e.g.*, an MTS™ tensile testing machine) operated at a separation rate of 1 mm/s to separate two collagen-coated, rubber

hemispheres compressed against one another, with a sample of the paste between them, using about a 4.4 Newton (1 pound) compression force. The rubber hemispheres desirably are made from ultra soft Shore OO, 30 durometer black rubber balls with a diameter of about 5 cm (2 inches) that have been bisected to a height of about 2.5 cm (1 inch). The hemispheres desirably are mounted in the tensile tester in opposing convex relationship with a piece of sausage casing wrapped over each hemisphere. About 0.2 to about 0.5 ml of the disclosed paste desirably is applied to the center of the lower hemisphere, the hemispheres are compressed together using the specified compression force and the force required to separate the hemispheres at the specified separation rate is recorded. Adhesion strength values are reported for sterilized paste. Desirably, the paste has a residence time in the applied passage or structure of at least 1 day, at least 3 days, at least 5 days, or at least 7 days with or without irrigation. The paste may degrade naturally or by irrigation (e.g., saline solution).

[0061] The disclosed paste desirably is non-cytotoxic with cytotoxicity scores of 0, 1 or 2 as measured by ISO Guideline 10993-5, Biological Evaluation of Medical Devices-Part 5: Tests for *in vitro* Cytotoxicity. Desirably, the paste may have a cytotoxicity score of 1 or less.

[0062] The disclosed paste desirably is substantially collagen-free. Desirably the paste is sufficiently free of collagen (e.g., containing no collagen at all) so as to be saleable worldwide for use without restriction in humans. The disclosed paste desirably does not contain other ingredients which might potentially harm mucosal tissues or structures, e.g., tissues in the nasal or sinus cavities.

[0063] The disclosed paste may be used as a part of a multi-step treatment regimen. For example, a series of steps that may be broadly classified as Cleansing/Disrupting, Killing, Aerating, Protecting/Coating, and Healing may be carried out. The Cleansing/Disrupting step may be carried out by administering a solvating system like those described in U.S. Patent Nos. 7,976,873 B2 and 7,976,875 B2 and in U.S. Patent Application Publication No. 2011/0245757A1. The Killing step may be carried out by applying a suitable antimicrobial agent to the treatment site. This may for example be accomplished by including an antimicrobial agent in the solvating system, as a separately-applied agent, or in both the solvating system and the separately-applied agent. An

antimicrobial agent may also be applied or administered post operatively. The Aerating step may be carried out by providing air passageways or improving air passageways to the treated tissues by opening occluded or partially occluded passages, *e.g.*, the sinuses or sinus ostia for nasal applications. This may for example be accomplished by surgically removing obstructive tissue structures or by manually displacing such structures. The Protecting/Coating step may be carried out by coating at least part of the thus-treated tissue with the disclosed paste. The Healing step may be carried out by allowing the cleansed, protected and sealed tissue surface to undergo a return to a normal state, *e.g.*, through one or more healing mechanisms such as modulation of an inflammatory response, phagocytosis, mucosal remodeling, reciliation or full or partial restoration of normal function. The multi-step treatment regimen may include or be followed by a Clearing step in which the disclosed paste is sufficiently biodegradable to disappear from the treatment site in a desired time period, *e.g.*, more than 5 days, or about 7 to 15 days or by irrigation. The paste desirably degrades or can be otherwise removed without shedding large solid chunks. The disclosed method may advantageously be accomplished without requiring surgery, for example by applying and removing the optional solvating system and by applying the disclosed paste through normal aspiration or suction techniques or by simple flushing of affected tissue.

[0064] The disclosed paste may be used for a variety of indications. Exemplary such indications include use as a stent or space occupying packing to separate tissue or structures compromised by surgical trauma, and to separate and prevent adhesions between mucosal surfaces in the nasal cavity. Other indications include the control via a tamponade effect, blood absorption or platelet aggregation of bleeding (*e.g.*, limited bleeding) and oozing of debrided mucosal surfaces following surgery or trauma, thereby aiding hemostasis; acting as an adjunct to aid in the natural healing process; acting as a nasal packing to treat epistaxis; and providing an antibacterial barrier or antibacterial effect.

[0065] The invention is further illustrated in the following non-limiting examples.

Example 1
Paste Formulations

[0066] A 3X PBS (pH 11-12) solution was prepared by dissolving PBS tablets in water and the pH was adjusted to pH 11-12 using 1N NaOH. Glycerol if used was then added to the PBS solution to form a PBS/Glycerol solution. To either the PBS solution or PBS/Glycerol solution were added varying amounts of dry ingredients, namely a 30-400 kDa molecular weight chitosan, glycerol phosphate disodium salt hydrate solid or polysaccharide and mixed at room temperature to form a paste. The paste was then gamma sterilized. All formulations except for formulation 4 formed a paste. Formulation 4 was initially liquid-like and subsequently became sticky and stringy. Table 1 shows the percentage of the ingredients in the total volume of liquid. Table 1 also shows the osmolality, viscosity and adhesion values for each formulation after sterilization.

Table 1

Formulation	Chitosan HCl (%)	Glycerol (%)	BGlyPh (%)	Polysaccharide (%)	Osmolality (mOsm/kg)	Sterile Viscosity (Pas.) at Shear Rate 221 (1/s)	Average Sterile Adhesion Force (grams)
1	13	0.6			2087	1.9	26.6
2	17	0.6			1730	3.2	26.4 – 37.7
3	17	0.6	6		2882	4.9	38.3
4	8.5		2	dextran (20%)	329	6.1	19.3
5	8.5		2	hydroxyethyl cellulose (2.5%)	495	NA	Less than 5
6	8.5		2	methyl cellulose (10%)	557	10.5	39.5
7	8.5		2	hydroxypropyl cellulose (15%)	177	8.2	33.1
8	13	0.6		hydroxypropyl cellulose (10%)	1492-2048	13.8	44.4
9	13	0.6		hydroxypropyl cellulose (5%)	2172	4.9	38.7
10	13	0.6		hydroxypropyl cellulose (1%)	2048-2067	1.6	24.3
11	17	0.6		hydroxypropyl cellulose (10%)	2100	10.7	62.2
12	17	0.6		hydroxypropyl cellulose (5%)	1787-1995	9.9	68.1
13	17	0.6		hydroxypropyl cellulose (1%)	2083	3.5	35.4

Example 2

[0067] 0.6 ml of 10 % glycerol and 5.4 ml of 3X PBS solution (pH 11) as prepared in Example 1 were mixed in a 10 ml syringe. To this PBS/Glycerol solution was added varying amounts of glycerol phosphate, chitosan *HCl* and hydroxypropyl cellulose (HPC) in solid form. After all the ingredients in the syringe were fully mixed at room temperature, the resultant paste was gamma or E-beam sterilized. The formulations are shown below in Table 2. All the formulations formed a paste at room temperature and remained a paste at room temperature. Table 2 shows the percentage of the various ingredients reported as a percentage of the total volume of liquid. The osmolality, viscosity and adhesion values for each formulation are shown below in Table 3 and are values after sterilization.

Table 2

Formulation	Chitosan HCl (%)	HPC (%)	Glycerol Phosphate (%)
14	8.5	3	1
15	13	4	2
16	10	3	1
17	10	3	1.5
18	13	2	2

Table 3

Formulation	Osmolality (mOsm/kg)	Sterile Viscosity (Pa.s.) at Shear Rate 221 (1/s) Gamma	Sterile Viscosity (Pa.s.) at Shear Rate 221 (1/s) E- Beam	Sterile Adhesion Force (grams) Gamma	Sterile Adhesion Force (grams) E-Beam
14	Less than 1492	3	3.2	13.5	40.6
15	Greater than or equal to 1492	1.7	0.4	14.5	45.5
16	525	1.8	2.3	22.8	65.0
17	Less than 1492	1.6	1.4	17.4	67.3
18	Greater than or equal to 1492	2.2	3.2	19.8	50.5

Example 3**Antimicrobial Properties**

[0068] Formulations 14, 15 and 16 from Table 2 were evaluated to determine their antimicrobial activity against four common bacterial strains (*S. aureus*, *S. epidermidis*, *E. coli* and *P. aeruginosa* using a zone of inhibition screening technique.

[0069] The four bacteria were grown on Muller Hinton agar plates. Under sterile conditions, approximately 0.1 to 0.2 ml of each formulation was directly placed on the agar plates. The agar plates were incubated at 35 °C for 12 hours. After incubation, the plates were observed for bacterial growth. The use of the term “zone of inhibition” denotes an area around the formulations where bacterial growth was inhibited. The term “bacteriostatic” denotes that the bacteria grew to the edge of the formulation but no further growth was observed. In other words, the term “bacteriostatic” refers to an ability to prevent bacteria from growing and multiplying but possibly not killing them.

[0070] The results shown in Table 4 below are based on triplicates per formulation.

Table 4
Antimicrobial Properties

Bacterial Strains	Zone of Inhibition or Bacteriostatic		
	Formulation 14	Formulation 15	Formulation 16
<i>S. aureus</i>	zone of inhibition	zone of inhibition	zone of inhibition
<i>S. epidermidis</i>	zone of inhibition	zone of inhibition	zone of inhibition
<i>E. coli</i>	zone of inhibition	zone of inhibition	zone of inhibition
<i>P. aeruginosa</i>	bacteriostatic	bacteriostatic	bacteriostatic

[0071] The results show that the formulations were antimicrobial and produced zones of inhibition.

[0072] Formulation 16 was evaluated according to United States Pharmacopeia (USP) Guidelines for Performing Antimicrobial Effectiveness Testing, Chapter <51> and Validation of Microbial Recovery, Chapter <1227> to determine antibacterial efficacy against common organisms typically found in treatment application areas. The measured antimicrobial properties are shown below in Table 5:

Table 5
Antimicrobial Properties, USP

Bacterial strain	ATCC No.	Gram stain	Antibacterial -Log Reduction			
			1 hour	24 hours	3 days	7 days
<i>Pseudomonas aeruginosa</i>	9027	neg	3	4.8	5.3	>5.3
<i>Staphylococcus aureus</i>	25923	pos	0	2.7	4	>5.0
<i>Staphylococcus epidermidis</i>	12228	pos	1.2	5.1	5	>5.3
<i>Escherichia coli</i>	25922	neg	0	1.6	3.9	>5.1
<i>Citrobacter freundii</i>	8090	neg	N/A	4.7	5	>5.3
<i>Enterobacter aerogenes</i>	13048	neg	N/A	2	2.3	>5.1
<i>Klebsiella pneumonia</i>	4352	neg	N/A	4	4	>5.2
<i>Proteus mirabilis</i>	4630	neg	N/A	2	4	>5.3
<i>Serratia marcescens</i>	13880	neg	N/A	1.5	2.8	>5.0
<i>Haemophilus influenzae</i>	53782	neg	N/A	>4.9	>4.9	>4.9
<i>Moraxella catarrhalis</i>	8193	neg	N/A	2.9	4	>5.0
<i>Staphylococcus aureus</i> (MRSA)	33591	pos	N/A	0.6	3.7	>5.1
<i>Staphylococcus saprophyticus</i>	15305	pos	N/A	4.6	4.9	>5.1
<i>Micrococcus luteus</i>	49732	pos	N/A	2.8	4	>5.0
<i>Streptococcus mutans</i>	25175	pos	N/A	3.4	4.4	>5.5
<i>Streptococcus pneumoniae</i>	10015	pos	N/A	2.5	3.6	>5.0
<i>Corynebacterium diphtheriae</i>	296	pos	N/A	1.6	>4.5	1.5
<i>Corynebacterium tuberculostearicum</i>	35693	pos	N/A	1.6	>5.1	3.9

Example 4
Cytotoxicity

[0073] Formulations 14 and 16 were either E-beam or gamma sterilized and were evaluated for potential cytotoxic effects following ISO Guideline 10993-5, Biological Evaluation of Medical Devices - Part 5: Tests for *in vitro* Cytotoxicity. Formulations 14 and 15 were extracted in purified water (PW) at 37° C for 24 hours. The PW extract was mixed with double strength Minimum Essential Medium (2X MEM) to a 50% concentration. A negative control (high density polyethylene) and reagent control (e.g., PW) were similarly prepared. A positive control (powder-free latex gloves which include natural rubber latex, zinc carbamate accelerators, zinc oxide and titanium dioxide) was extracted in single strength MEM (1X MEM) at 37° C for 24 hours. Triplicates of a mammalian cell culture monolayer having L-929 mouse fibroblast cells were dosed with each extract (formulations 14, 16, positive, negative and reagent controls) and incubated at 37° C in the presence of 5% CO₂ for 48 hours. Following incubation, the monolayers were examined microscopically (100X) for abnormal cell morphology and cellular degeneration.

[0074] To confirm the scores, 0.2 ml of trypan blue stain was added to wells containing the test samples. The trypan blue molecule is large and cannot readily be absorbed by live cells. Only dead cells or those with compromised cell membranes take up the blue colored stain. Table 6 describes the scoring and visual characteristics.

Table 6

Grade/Score	Reactivity	Conditions of all Cultures
0	None	Discrete intracytoplasmic granules, no cell lysis, no reduction of cell growth.
1	Slight	Not more than 20% of the cells are round, loosely attached and without intracytoplasmic granules, or show changes in morphology; occasional lysed cells are present; only slight growth inhibition observable.
2	Mild	Not more than 50% of the cells are round, devoid of intracytoplasmic granules; no extensive cell lysis; not more than 50% growth inhibition observable.
3	Moderate	Not more than 70% of the cell layers contain rounded cells or are lysed; cell layers not completely destroyed, but more than 50% growth inhibition observed.
4	Severe	Nearly complete or complete destruction of the cell layers.

[0075] Set out below in Table 7 are the results for either E-beam (e) or gamma (g) sterilized versions of Formulations 14 and 16, with the subscripts e or g denoting the sterilization method:

Table 7
Cytotoxicity

Sample	Percent Rounding	Percent Cells Without Intracytoplasmic Granules	Percent Lysis	Grade	Reactivity
Formulation 14 _e	0	0	0	0	None
Formulation 14 _g	0	0	0	0	None
Formulation 16 _e	10	10	10	1	Slight
Formulation 16 _g	0	0	0	0	None
Negative Control	0	0	0	0	None
Reagent Control	0	0	0	0	None
Positive Control	Not Applicable	Not Applicable	100	4	Severe

[0076] Formulation 16_e showed slight cell lysis or toxicity but is generally considered to be non-cytotoxic with a cytotoxicity score of 1. Formulations 16_g, 14_e and 14_g were shown to be nontoxic with each having a cytotoxicity score of 0.

Example 5
Ciliotoxicity in Rabbits

[0077] Formulations 14 and 16 were either E-beam or gamma sterilized and evaluated for their effect on rabbit cilia. A 0.6 cc portion of each formulation (Formulations 14, 16 and control (no treatment, saline only)) were applied to the bilateral maxillary sinus antrostomies of randomized New Zealand White rabbits using a single lumen catheter. Following treatment, daily irrigation with 3 cc of saline was performed. At the end of 7 or 10 days, the rabbits were euthanized, and a piece of the medial wall of the maxillary sinuses was removed and fixed (Karnovsky's fixture) for scanning electron microscopy (SEM).

[0078] In a blind analysis, the tissues samples were evaluated and scored for the presence or absence of cilia. The results are shown in Table 8.

Table 8
Ciliotoxicity in Rabbits

Formulation	E-beam	Gamma
Saline control	Cilia present	Cilia present
14	Cilia present	Cilia present
16	Cilia present	Cilia present

[0079] Rabbits treated with the formulations showed the presence of cilia similar to the saline control. These results suggest that these formulations were non-toxic to cilia. In addition, the sterilization method did not appear to affect the formulation's toxicity towards cilia, namely both gamma and E-beam sterilized formulations were non-toxic to cilia.

Example 6
Ciliotoxicity in Sheep

[0080] Endoscopic sinus surgery including bilateral middle turbinatectomy and partial thickness wounding around the ethmoidal cell was performed on sheep. The sheep were randomized and one nare was treated with 7 ml of each test formulation (formulation 7 and 8), the other nare with no treatment (control). Daily bilateral 20cc saline irrigations were performed through the nose. Twenty-eight days after the surgery, two pieces of the medial wall of the nasal/sinus cavity were obtained from each sheep and each piece was fixed either for SEM analysis (Karnovsky's fixative) or histology or pathology evaluation (formalin). In a blind analysis, the tissue samples were evaluated and scored for the presence or absence of cilia.

[0081] No paste material was observed in the sheep after 28 days. SEM analysis showed cilia were present in both treated and control samples. Microscopic evaluation revealed similar inflammatory response between the treated samples and control. These results suggest that the formulations are safe for use *in vivo*.

Example 7**Sensitization and Irritation**

[0082] Formulation 16 was evaluated for sensitization using a guinea pig model and ISO Guideline 10993-10, Biological Evaluation of Medical Devices - Part 10: Tests for irritation and skin sensitization. The formulation received sensitization scores of 0 for all test sites in a guinea pig model, and did not show any evidence of a delayed reaction. The formulation also received an irritation index of 0 using microscopic evaluation of vaginal mucosal tissue in a rabbit model. The formulation would not be considered a sensitizer or an irritant under the ISO Guideline.

[0083] Formulation 16 was also evaluated for sensitization using an ELISA Protein Analysis. The formulation was found to contain 5.1 ppm shellfish allergen or 0.00051% shellfish protein, with a 2 ppm limit of detection.

Example 8**Acute Systemic Toxicity**

[0084] Formulation 16 was evaluated for acute systemic toxicity using a rat model, a 5 g/Kg oral route dose and ISO Guideline 10993-11, Biological Evaluation of Medical Devices - Part 11: Tests for systemic toxicity. For a packaged product for use in adult humans containing about 12 g of the disclosed paste, the chosen 5/g/kg test dose would represent about 29 times the adult dose. All animals survived the study.

Example 9**Residence Time**

[0085] Formulation 16 was evaluated to determine its residence time and the formation of adhesions following application to wounded tissues in the nasal cavities of ten adult sheep. All animals in the study tolerated the procedure well and nine displayed a normal post-operative recovery with minimal adverse events. The observed residence time was 7 to 14 days and no adhesions were present in any of the animals during the study.

[0086] Some additional non-limiting embodiments are provided below to further exemplify the present invention:

1. A paste in sterile packaging comprising a water-soluble chitosan, an osmolality reducing agent and a lubricating or wetting agent dissolved in a phosphate-containing solution to provide a paste at room temperature having a pH of at least 4, wherein the osmolality reducing agent is not crosslinkable with the water-soluble chitosan and the paste has a viscosity of about 1 to about 15 Pa.s. and an osmolality of about 270 to about 2000 mOsm/kg, and the paste adheres to a tissue site and has a residence time of at least 1 day.
2. A sinus stent paste comprising a water-soluble chitosan, an osmolality reducing agent and a lubricating or wetting agent dissolved in a phosphate-containing solution to provide a paste at room temperature having a pH of at least 4, wherein the paste has a viscosity of about 1 to about 15 Pa.s., an osmolality of about 270 to about 2000 mOsm/kg and a residence time of at least 1 day and the osmolality reducing agent does not crosslink with the water-soluble chitosan.
3. A method for producing a paste comprising:
mixing and dissolving a water-soluble chitosan, an osmolality reducing agent and a lubricating or wetting agent in a phosphate-containing solution to provide a paste at room temperature having a pH of at least 4, wherein the paste has a viscosity of about 1 to about 15 Pa.s., an osmolality of about 270 to about 2000 mOsm/kg and a residence time of at least 1 day and the osmolality reducing agent does not crosslink with the water-soluble chitosan.
4. The embodiment 1, 2 or 3 wherein the water-soluble chitosan comprises a salt.
5. Any of embodiments 1 to 4 wherein the water-soluble chitosan comprises a hydrochloric acid salt.
6. Any of embodiments 1 to 5 wherein the water-soluble chitosan is about 3-20 wt. % of total paste weight.

7. Any of embodiments 1 to 6 wherein the osmolality reducing agent comprises a hydroxyl-functional or alkyl-modified cellulose.
8. The embodiment 7 wherein the hydroxyl-functional or alkyl-modified cellulose is hydroxypropyl cellulose, methyl cellulose or hydroxyethyl cellulose.
9. Any of embodiments 1 to 8 wherein the lubricating or wetting agent comprises glycerol.
10. Any of embodiments 1 to 9 wherein the phosphate-containing solution is a phosphate-buffered saline (PBS).
11. Any of embodiments 1 to 10 wherein the phosphate-containing solution is a 3x PBS solution.
12. Any of embodiments 1 to 11 wherein the phosphate-containing solution has a pH between 9 and 12.
13. Any of embodiments 1 to 12 wherein the sterile packaging is electron-beam or gamma sterilized.
14. The embodiment 13 wherein the sterilization energy is between about 12 to about 40 kGy.
15. Any of embodiments 1 to 14 wherein the residence time is at least 3 days.
16. Any of embodiments 1 to 15 having an adhesive strength of between about 5 grams and about 80 grams of force required when using a tensile testing machine operated at a separation rate of 1 mm/s to separate two collagen-coated rubber hemispheres that have been compressed against one another, with a sample of the paste between them, using about a 4.4 Newton compression force.
17. Any of embodiments 1 to 16 that is non-cytotoxic.
18. The embodiment 17 having a cytotoxicity score of 1 or less.

19. Any of embodiments 1 to 18 further comprising glycerol phosphate.
20. A stent or packing formed from the composition of any of embodiments 1 to 19.
21. The stent or packing of embodiment 20 wherein the stent or packing contacts a nasal or sinus passage.

[0087] All patents, patent applications and literature cited in the specification are hereby incorporated by reference in their entirety. In the case of any inconsistencies, the present disclosure, including any definitions therein will prevail. Although specific embodiments have been illustrated and described herein for purposes of description of the preferred embodiments, it will be appreciated by those of ordinary skill in the art that a wide variety of alternate or equivalent implementations calculated to achieve the same purposes may be substituted for the specific embodiments shown and described without departing from the present invention. This application is intended to cover any adaptations or variations of the preferred embodiments discussed herein. Therefore, it is manifestly intended that this invention be limited only by the claims and the equivalents thereof.

We claim:


1. A sinus stent paste comprising a water-soluble chitosan or derivative thereof and an osmolality reducing agent dissolved in a phosphate-containing solution to provide an opaque paste at room temperature containing at least 5 wt. % of the water-soluble chitosan or derivative thereof based on the total paste weight and having a pH of at least 4, a viscosity of about 1 to about 15 Pa.s., an osmolality of about 270 to about 2000 mOsm/kg, and a residence time of at least 1 day, wherein the osmolality reducing agent does not crosslink with the water-soluble chitosan.
2. A method for preparing a chitosan stenting paste comprising the steps of:
mixing and dissolving a water-soluble chitosan or derivative thereof and an osmolality reducing agent in a phosphate-containing solution to provide an opaque paste at room temperature containing at least 5 wt. % of the water-soluble chitosan or derivative thereof based on the total paste weight and having a pH of at least 4, a viscosity of about 1 to about 15 Pa.s., an osmolality of about 270 to about 2000 mOsm/kg, and a residence time of at least 1 day wherein the osmolality reducing agent does not crosslink with the water-soluble chitosan.
3. A method for stenting comprising:
 - a) providing a composition comprising a water-soluble chitosan or derivative thereof and an osmolality reducing agent dissolved in a phosphate-containing solution to provide an opaque paste at room temperature containing at least 5 wt. % of the water-soluble chitosan or derivative thereof based on the total paste weight and having a pH of at least 4, a viscosity of about 1 to about 15 Pa.s., and an osmolality of about 270 to about 2000 mOsm/kg wherein the osmolality reducing agent does not crosslink with the water-soluble chitosan; and
 - b) applying the paste onto a nasal or sinus site to form a protective packing, layer or stent wherein the paste adheres to the nasal or sinus site and has a residence time of at least 1 day.
4. A paste or method according to any preceding claim wherein the water-soluble chitosan comprises a hydrochloric acid salt.

5. A paste or method according to any preceding claim wherein the water-soluble chitosan is about 8 to about 20 wt. % of the total paste weight.
6. A paste or method according to any preceding claim wherein the water-soluble chitosan is about 12 wt. % to about 18 wt. % of the total paste weight.
7. A paste or method according to any preceding claim wherein the water-soluble chitosan has a number average molecular weight of about 5 to about 2000 kDa.
8. A paste or method according to any preceding claim wherein the water-soluble chitosan has a number average molecular weight of about 30 to about 400 kDa.
9. A paste or method according to any preceding claim wherein the osmolality reducing agent comprises a hydroxyl-functional or alkyl-modified cellulose.
10. The paste or method according to claim 9 wherein the hydroxyl-functional or alkyl-modified cellulose is hydroxypropyl cellulose, methyl cellulose or hydroxyethyl cellulose.
11. A paste or method according to any preceding claim wherein the osmolality reducing agent is about 1 to about 20 wt. % of the total paste weight.
12. A paste or method according to any preceding claim wherein the phosphate-containing solution is a phosphate-buffered saline having a pH of 9 to 12.
13. A paste or method according to any preceding claim wherein the paste has been sterilized in sealed packaging.
14. The paste or method according to claim 13 wherein the paste and its sealed packaging have been sterilized by electron-beam radiation or gamma radiation.
15. A paste or method according to any preceding claim wherein the paste is sterilized and has an adhesive strength of between about 5 grams and about 80 grams of force required when using a tensile testing machine operated at a separation rate of 1mm/s to separate two collagen-coated rubber hemispheres that have been compressed against one another, with a sample of the paste between them, using about a 4.4 Newton compression



force.

16. A paste or method according to any preceding claim wherein the paste is non-cytotoxic with a cytotoxicity score of 1 or less as measured by ISO Guideline 10993-5, Biological Evaluation of Medical Devices-Part 5: Tests for in vitro Cytotoxicity.
17. A paste or method according to any preceding claim wherein the phosphate-containing solution comprises a glycerol phosphate.
18. A paste or method according to any preceding claim further comprising about 1 wt. % to about 10 wt. % of a lubricant or wetting agent based on the total paste weight.
19. The paste or method according to claim 18 wherein the lubricant or wetting agent is glycerol.
20. A paste or method according to any preceding claim wherein the paste is packaged as a ready-to-use composition.

1/2

**Fig. 1**

2/2

**Fig. 2****Fig. 3**